Expression of estrogen receptors in gastric cancer and their clinical significance

Woo Sang Ryu, Jong Han Kim, You-Jin Jang, Sungsoo Park, Jun Won Um, Seong-Heum Park, Seung Joo Kim, Young Jae Mok, Chong Suk Kim

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Backgrounds and Objectives The male predominance of gastric cancer suggests that female sex hormones may have a protective effect against gastric cancer. We evaluated the expression of estrogen receptors in gastric cancer tissue and cells and the clinical significance of ER-β expression in gastric cancer. Method ER-α, ER-β proteins extracted from normal stomach, gastric cancer tissues, and cultured gastric cancer cells (KATO-III, mkn28, mkn45, and mkn74) were assessed by Western blot analysis. The clinical significance of ER-β was explored using tissue microarray methods and immunohistochemical staining of specimens from 148 gastric cancers. Results Both ER-α and β protein expression were noted in normal and gastric cancer tissues. However, in cultured gastric cells, only ER-β was noted in mkn28 and mkn74. Of 148 gastric cancers, 67 (45.3%) were ER-β positive. The ER-β positive group was associated with lower tumor stage, Lauren's intestinal type, negative perineural invasion, and free of recurrence. The ER-β positive group had a better 3-year survival compared with the negative group in survival analysis. Conclusion Our results suggest that the presence of ER-β in gastric cancer could have a protective effect against invasiveness of gastric cancer. Further studies are needed to clarify the role of ER-β in gastric cancers. J. Surg. Oncol. 2012; 106:456-461. © 2012 Wiley Periodicals, Inc.

Original languageEnglish
Pages (from-to)456-461
Number of pages6
JournalJournal of Surgical Oncology
Volume106
Issue number4
DOIs
Publication statusPublished - 2012 Sep 15

Fingerprint

Estrogen Receptors
Stomach Neoplasms
Gonadal Steroid Hormones
Survival Analysis
Cultured Cells
Stomach
Proteins
Western Blotting
Staining and Labeling
Recurrence

Keywords

  • estrogen receptor α
  • estrogen receptor β
  • gastric cancer

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Expression of estrogen receptors in gastric cancer and their clinical significance. / Ryu, Woo Sang; Kim, Jong Han; Jang, You-Jin; Park, Sungsoo; Um, Jun Won; Park, Seong-Heum; Kim, Seung Joo; Mok, Young Jae; Kim, Chong Suk.

In: Journal of Surgical Oncology, Vol. 106, No. 4, 15.09.2012, p. 456-461.

Research output: Contribution to journalArticle

@article{2b8deae1f4474e8eb89f7d0b8b1957d6,
title = "Expression of estrogen receptors in gastric cancer and their clinical significance",
abstract = "Backgrounds and Objectives The male predominance of gastric cancer suggests that female sex hormones may have a protective effect against gastric cancer. We evaluated the expression of estrogen receptors in gastric cancer tissue and cells and the clinical significance of ER-β expression in gastric cancer. Method ER-α, ER-β proteins extracted from normal stomach, gastric cancer tissues, and cultured gastric cancer cells (KATO-III, mkn28, mkn45, and mkn74) were assessed by Western blot analysis. The clinical significance of ER-β was explored using tissue microarray methods and immunohistochemical staining of specimens from 148 gastric cancers. Results Both ER-α and β protein expression were noted in normal and gastric cancer tissues. However, in cultured gastric cells, only ER-β was noted in mkn28 and mkn74. Of 148 gastric cancers, 67 (45.3{\%}) were ER-β positive. The ER-β positive group was associated with lower tumor stage, Lauren's intestinal type, negative perineural invasion, and free of recurrence. The ER-β positive group had a better 3-year survival compared with the negative group in survival analysis. Conclusion Our results suggest that the presence of ER-β in gastric cancer could have a protective effect against invasiveness of gastric cancer. Further studies are needed to clarify the role of ER-β in gastric cancers. J. Surg. Oncol. 2012; 106:456-461. {\circledC} 2012 Wiley Periodicals, Inc.",
keywords = "estrogen receptor α, estrogen receptor β, gastric cancer",
author = "Ryu, {Woo Sang} and Kim, {Jong Han} and You-Jin Jang and Sungsoo Park and Um, {Jun Won} and Seong-Heum Park and Kim, {Seung Joo} and Mok, {Young Jae} and Kim, {Chong Suk}",
year = "2012",
month = "9",
day = "15",
doi = "10.1002/jso.23097",
language = "English",
volume = "106",
pages = "456--461",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Expression of estrogen receptors in gastric cancer and their clinical significance

AU - Ryu, Woo Sang

AU - Kim, Jong Han

AU - Jang, You-Jin

AU - Park, Sungsoo

AU - Um, Jun Won

AU - Park, Seong-Heum

AU - Kim, Seung Joo

AU - Mok, Young Jae

AU - Kim, Chong Suk

PY - 2012/9/15

Y1 - 2012/9/15

N2 - Backgrounds and Objectives The male predominance of gastric cancer suggests that female sex hormones may have a protective effect against gastric cancer. We evaluated the expression of estrogen receptors in gastric cancer tissue and cells and the clinical significance of ER-β expression in gastric cancer. Method ER-α, ER-β proteins extracted from normal stomach, gastric cancer tissues, and cultured gastric cancer cells (KATO-III, mkn28, mkn45, and mkn74) were assessed by Western blot analysis. The clinical significance of ER-β was explored using tissue microarray methods and immunohistochemical staining of specimens from 148 gastric cancers. Results Both ER-α and β protein expression were noted in normal and gastric cancer tissues. However, in cultured gastric cells, only ER-β was noted in mkn28 and mkn74. Of 148 gastric cancers, 67 (45.3%) were ER-β positive. The ER-β positive group was associated with lower tumor stage, Lauren's intestinal type, negative perineural invasion, and free of recurrence. The ER-β positive group had a better 3-year survival compared with the negative group in survival analysis. Conclusion Our results suggest that the presence of ER-β in gastric cancer could have a protective effect against invasiveness of gastric cancer. Further studies are needed to clarify the role of ER-β in gastric cancers. J. Surg. Oncol. 2012; 106:456-461. © 2012 Wiley Periodicals, Inc.

AB - Backgrounds and Objectives The male predominance of gastric cancer suggests that female sex hormones may have a protective effect against gastric cancer. We evaluated the expression of estrogen receptors in gastric cancer tissue and cells and the clinical significance of ER-β expression in gastric cancer. Method ER-α, ER-β proteins extracted from normal stomach, gastric cancer tissues, and cultured gastric cancer cells (KATO-III, mkn28, mkn45, and mkn74) were assessed by Western blot analysis. The clinical significance of ER-β was explored using tissue microarray methods and immunohistochemical staining of specimens from 148 gastric cancers. Results Both ER-α and β protein expression were noted in normal and gastric cancer tissues. However, in cultured gastric cells, only ER-β was noted in mkn28 and mkn74. Of 148 gastric cancers, 67 (45.3%) were ER-β positive. The ER-β positive group was associated with lower tumor stage, Lauren's intestinal type, negative perineural invasion, and free of recurrence. The ER-β positive group had a better 3-year survival compared with the negative group in survival analysis. Conclusion Our results suggest that the presence of ER-β in gastric cancer could have a protective effect against invasiveness of gastric cancer. Further studies are needed to clarify the role of ER-β in gastric cancers. J. Surg. Oncol. 2012; 106:456-461. © 2012 Wiley Periodicals, Inc.

KW - estrogen receptor α

KW - estrogen receptor β

KW - gastric cancer

UR - http://www.scopus.com/inward/record.url?scp=84865121899&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865121899&partnerID=8YFLogxK

U2 - 10.1002/jso.23097

DO - 10.1002/jso.23097

M3 - Article

C2 - 22422271

AN - SCOPUS:84865121899

VL - 106

SP - 456

EP - 461

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 4

ER -